EcoDrugPlus

Chemokine (C-C Motif) Receptor 9b

Ensembl ID : ENSMAMG00000010895
Gene Symbol: CCR9B
2 Cross references
193 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 2

Ensembl ID : ENSMAMG00000027889
Gene Symbol: CXCR2
2 Cross references
275 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSMAMG00000000922
Gene Symbol: CCKAR
4 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSMAMG00000008497
Gene Symbol: CCKBRA
3 Cross references
193 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSMAMG00000014998
Gene Symbol: LOC113123106
2 Cross references
191 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSMAMG00000009630
Gene Symbol: LOC113137108
2 Cross references
255 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSMAMG00000009573
Gene Symbol: LOC113137109
2 Cross references
255 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSMAMG00000025520
Gene Symbol: LOC113137113
2 Cross references
255 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSMAMG00000025161
Gene Symbol: LOC113137110
2 Cross references
255 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSMAMG00000013972
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSMAMG00000016218
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSMAMG00000003136
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).